Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system

Archives of Gynecology and Obstetrics

Volumn 281, Issue 4, 2010, Pages 683-695

  Tang, Chao Hsiun ^a,b   Pwu, Raoh Fang ^a,c   Tsai, I Ching ^d   Wang, Han I ^a   You, San Lin ^e,f   Chen, Chi An ^g   Scuffham, Paul A ^h   Hsieh, Chang Yao ^g   Chou, Cheng Yang ⁱ   Lin, Sheue Rong ^j   Chen, Yao Der ^k   Chen, Chien Jen ^l  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Center for Drug Evaluation   (Taiwan)

^d Janssen Cilag Taiwan   (Taiwan)

^e GENOMICS RESEARCH CENTER   (Taiwan)

^f NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h GRIFFITH UNIVERSITY   (Australia)

ⁱ NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^j Executive Yuan   (Taiwan)

^k DEPARTMENT OF HEALTH   (Taiwan)

^l NATIONAL TAIWAN UNIVERSITY   (Taiwan)

more..

Author keywords

Cervical cancer; Cost; Health Care

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; NATIONAL HEALTH INSURANCE; PRECANCER; TAIWAN; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; TAIWAN; UTERINE CERVICAL NEOPLASMS;

EID: 77950605796     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-1218-6     Document Type: Article

References (34)

1. Bureau of Health Promotion (2006) Annual report of cancer registration. Bureau of Health Promotion, Department of Health, Taipei, Taiwan
2. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW (2002) Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 32:S66-S81
3. Department of Health (2007) Health and vital statistics. Department of Health, Executive Yuan, Republic of China, Taipei, Taiwan, December, 2008
4. Department of Health (2006) Pap smear screening registry system annual report. Department of Health, Taipei, Taiwan, December, 2007
5. Taiwan Cooperative Oncology Group (2007) Clinical practice guidelines for gynecologic oncology. National Health Research Institutes, Taiwan Cooperative Oncology Group, August 2007
6. van Ballegooijen M, van den Akker-van Marle E, Patnick J, Lynge E, Arbyn M et al (2000) Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 36(17):2177-2188
7. Franco EI, Rohan TE, Villa LL (1999) Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91(6):506-511
8. Bosch FX, Lorinca A, Nunoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244-265
9. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447):1757-1765
10. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6(5):271-278
11. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ et al (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107(1):18-27
12. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367(9518):1247-1255
13. van Ballegooijen M, Koopmanschap MA, Habbema JD (1995) The management of cervical intra-epithelial neoplasia (CIN): extensiveness and costs in the Netherlands. Eur J Cancer 31A(10):1672-1676
14. Kavanagh AM, Butler JR (1998) The short-term financial costs of abnormal Pap smears to women and government in Australia. Aust N Z J Public Health 22(3 Suppl):347-352
15. Bergeron C, Breugelmans JG, Bouée S, Lorans C, Bénard S, Rémy V (2006) Cervical cancer screening and associated treatment costs in France. Gynecol Obstet Fertil 34(11):1036-1042
16. Wolstenholme JL, Whynes DK (1998) Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer 34(12):1889-1893
17. Insinga RP, Glass AG, Rush BB (2004) The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 191(1):114-120
18. Brown RE, Breugelmans JG, Theodoratou D, Benard S (2006) Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 22(4):663-670
19. Cantor SB, Levy LB, Cardenas-Turanzas M, Basen-Engquist K, Le T et al (2006) Collecting direct non-health care and time costs data: application to screening and diagnosis of cervical cancer. Med Decis Making 26(3):265-272
20. Department of Health, Republic of China, Health and National Health Insurance Annual Statistics Information Services, Summary of National Health Insurance. http://www.doh.gov.tw/statistic/data. Accessed 31 January 2006
21. Directorate General of Budget, Accounting and Statistics, Republic of China. Resident Population by 5-year age group. http://sowf.moi.gov.tw/stat/ month/m1-06.xls. Accessed 31 Jan 2006
22. Yeh SC (2003) Burden of out-of-pocket payments associated with outpatient care in National Health Insurance Program. Final Report of the 2nd Generation of NHI, the Task Force of 2nd Generation of NHI, Executive Yuan, Republic of China
23. Hsu HC (2003) Burden of out-of-pocket payments associated with inpatient care in National Health Insurance Program. Final Report of the 2nd Generation of NHI, the Task Force of 2nd Generation of NHI, Executive Yuan, Republic of China
24. Directorate General of Budget, Accounting and Statistics (2004) Report on the manpower utilization survey. Directorate General of Budget, Accounting and Statistics, Executive Yuan, Republic of China, Taipei, Taiwan
25. Directorate General of Budget, Accounting and Statistics, Executive Yuan, Republic of China. http://www.dgbas.gov.tw/public/data/dgbas03/bs3/inquire/ cpispl.xls. Accessed 31 January 2006
26. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT et al (2002) Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287(18):2372-2381
27. McCrory DC, Matchar DB, Bastian L, Datta S, Hasselblad V, Hickey J et al (1999) Evaluation of cervical cytology. Evid Rep Technol Assess (Summ) (5):1-6
28. Baker MS, Keller LG, Urban N, Smucker RC (1991) Estimating the treatment costs of breast and lung cancer. Med Care 29(1):40-49
29. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L et al (1995) Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer. J Natl Cancer Inst 87(6):417-426
30. Brown JL, Riley GF, Potosky AL, Etzioni RD (1999) Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 37(12): 1249-1259
31. Drummond MF, Schlpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, USA, pp 55-101
32. Dickson RJ (1980) Management of carcinoma of the cervix. Practitioner 224(1347):899-904
33. National Health Insurance Medical Expenditure Negotiation Committee (2006) Negotiation indices for global budget payment system under the National Health Insurance Program. September 2006. National Health Insurance Medical Expenditure Negotiation Committee, Department of Health, Executive Yuan, Taipei, Taiwan
34. Rice DP (2000) Cost of illness studies: what is good about them? Inj Prev 6(3):17-177